Results 291 to 300 of about 112,050 (329)
Some of the next articles are maybe not open access.
Mitochondria, monoamine oxidase B and Parkinson’s disease
Basal Ganglia, 2012Abstract The cause of cell death in Parkinson’s disease (PD) remains unclear but it is multifactorial with a complex interaction between a range of pathogenic mechanisms. However, alterations in mitochondrial function have been clearly linked to nigral dopaminergic loss in sporadic PD and to the effects of gene mutations in familial forms of the ...
openaire +1 more source
Chalcones: Unearthing their therapeutic possibility as monoamine oxidase B inhibitors.
European journal of medicinal chemistry, 2020Paolo Guglielmi +3 more
semanticscholar +1 more source
Oxidase reactions in photoredox catalysis
Chemical Society Reviews, 2021Nicholas L Reed, Tehshik P Yoon
exaly
Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders
Nature Structural Biology, 2002C. Binda +4 more
semanticscholar +1 more source
Inhibition of monoamine oxidase B in the brains of smokers
Nature, 1996J. Fowler +13 more
semanticscholar +1 more source
Pharmacology of Monoamine Oxidase Type B Inhibitors
1993Monoamine oxidase (MAO; EC 1.4.3.4.) plays an essential role in the oxidative deamination of biogenic and food-derived amines, both in the central nervous system and the peripheral tissues. The enzyme was first described by Hare as tyramine oxidase [1] and was called monoamine oxidase by Zeller [2] in 1938. MAO is prevalent in animals [3].
openaire +1 more source
Monoamine oxidase B and Parkinson's disease
The Lancet, 1990G Steventon +4 more
openaire +1 more source
Catalytic chemistry of glucose oxidase in cancer diagnosis and treatment
Chemical Society Reviews, 2018Lian-Hua Fu, Chao Qi, Jing Lin
exaly